MARKER THERAPEUTICS, INC.
MT-601, a multi-tumor associated antigen (mTAA)-specific autologous T cell immunotherapy for Non-Hodgkin's Lymphoma
- Sector
- Biotech
- Headquarters
- HOUSTON, TX
- Latest Form D
- $16.1M, Dec 2024
- Total capital
- $36.9M
- Federal grants
- $6.7M
- 9 awards · 2023–2025
- Rank in peer group#86 of 514
- Private capital raised
- $30.3M
- 9 Form D · last Dec 2024
- 22 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 9 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX$674K
- Federal grantHealth and Human S · Phase II · Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant$665K
- Federal grantHealth and Human S · Phase II · A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma$665K
- Federal grantHealth and Human S · Phase II · Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy$1.3M
- Private capital raisedForm D · SEC · 8th filing$16.1M
- Federal grantHealth and Human S · Phase II · Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant$665K
- Federal grantHealth and Human S · Phase II · A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX$674K
- Private capital raisedForm D · SEC · 7th filing$3.1M
- Private capital raisedForm D · SEC · 6th filing$6.2M
- Private capital raisedForm D · SEC · 5th filing$2.4M
- Private capital raisedForm D · SEC · 4th filing$1.3M
- Private capital raisedForm D · SEC · 3rd filing$700K
- Private capital raisedForm D · SEC · 2nd filing$350K
- Private capital raisedForm D · SEC · 1st filing$135K
Show 3 earlier federal awards
- Federal grantHealth and Human S · Phase II · A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma$665K
- Federal grantHealth and Human S · Phase II · Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy$651K
- Federal grantHealth and Human S · Phase II · Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant$665K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#86 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- David EansorDirectorNamed in SEC Form D filings
- John WilsonDirectorNamed in SEC Form D filings
- Juan VeraExecutive Officer, DirectorNamed in SEC Form D filings
- Katharine KnobilDirectorNamed in SEC Form D filings
- Steven ElmsDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 9- PendingCompositions And Methods For Antigen-specific T Cell ExpansionUSPTOApplication 18805940
- PendingChimeric Nucleic Acid Molecules With Non-aug Translation Initiation Sequences And Uses ThereofUSPTOApplication 17222910
- PendingChimeric Nucleic Acid Molecules With Non-aug Translation Initiation Sequences And Uses ThereofUSPTOApplication 17189120
Show all 9 patent records
- Compositions And Methods For Antigen-specific T Cell ExpansionDec 5, 2024 · Application 18805940Pending
- Chimeric Nucleic Acid Molecules With Non-aug Translation Initiation Sequences And Uses ThereofFeb 24, 2022 · Application 17222910Pending
- Chimeric Nucleic Acid Molecules With Non-aug Translation Initiation Sequences And Uses ThereofFeb 3, 2022 · Application 17189120Pending
- Chimeric Nucleic Acid Molecules With Non-aug Translation Initiation Sequences And Uses ThereofAug 16, 2018 · Application 15882626Pending
- Chimeric Nucleic Acid Molecules With Non-aug Translation Initiation Sequences And Uses ThereofJun 14, 2018 · Application 15882724Pending
- Compositions And Methods For Antigen-specific T Cell ExpansionApplication 63310500Pending
- Compositions And Methods For Antigen-specific T Cell ExpansionApplication PCTUS2023062689Pending
- Chimeric Nucleic Acid Molecules With Non-aug Translation Initiation Sequences And Uses ThereofApplication 16996801Pending
- Chimeric Nucleic Acid Molecules With Non-aug Translation Initiation Sequences And Uses ThereofApplication 16890921Pending
Related companies, and why
- UNCO THERAPEUTICS LLCSimilar federal contract value in Biotech · null in contracts
- Inspira Therapeutics, IncSimilar federal contract value in Biotech · null in contracts
- SAVARA, INC.Similar federal contract value in Biotech · null in contracts
- ACHIEVE LIFE SCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- CELLIBRE INCSimilar federal contract value in Biotech · null in contracts
- ALIDA BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .